Oncology’s New Bottleneck Is Becoming Treatment Matching
As therapies become more complex and more expensive, biotech is discovering that the next moat may lie in predicting response…
Author: Jane Aubrey
Jane Aubrey brings over a decade of experience as a clinical researcher to her reporting on drug development and regulatory pathways. At The Biotech Codex, she breaks down complex trial data and analyzes the pipeline strategies of both emerging biotechs and legacy pharma giants. Her coverage demystifies the arduous journey from bench to bedside, keeping industry professionals informed on the latest therapeutic breakthroughs.
Biotech’s Market Is Open Again, but Only for the Most Credible Stories
The current biotech tape is not broadly forgiving. It is rewarding scalable platforms, manufacturing leverage, and differentiated clinical assets while…
The Personalized Vaccine Revolution: mRNA Rewrites the Rules of Cancer Immunotherapy
Five-year melanoma data and early breakthroughs in pancreatic and brain cancers signal that individualized mRNA vaccines are maturing from proof…
The Liquid Biopsy Reality Check: Navigating the Promise and Limits of Blood-Based Cancer Detection
As multi-cancer early detection tests generate immense excitement, oncologists emphasize the need for rigorous clinical validation and temper expectations regarding…
Beyond the Short Read: How Long-Read Sequencing is Solving the Unsolvable
A landmark study demonstrates that long-read genome sequencing can replace 15 separate diagnostics for rare genetic diseases, while also illuminating…
A Milestone in Gene Therapy: Restoring Sound and the Base Editing Debate
The FDA’s landmark approval of an in vivo gene therapy for hearing loss signals a new era for biotechnology, even…
The Unraveling of the Managed Care Model: How UnitedHealth’s Crisis is Reshaping the Insurance Landscape
As federal investigations, state lawsuits, and bipartisan pushback against AI-driven prior authorization converge, the health insurance industry faces a profound…